Parallel Arm Trial of AD109 and AD504 In Patients With OSA

PHASE2CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

July 20, 2022

Study Completion Date

August 3, 2022

Conditions
OSA - Obstructive Sleep Apnea
Interventions
DRUG

AD109

Oral administration at bedtime

DRUG

AD504

Oral administration at bedtime

DRUG

Atomoxetine Hydrochloride

Oral administration at bedtime

DRUG

Placebo

Oral administration at bedtime

Trial Locations (25)

10016

Clinilabs, New York

19355

Brian Abaluck, LLC, Malvern

20815

The Center for Sleep & Wake Disorders, Chevy Chase

21061

Sleep Disorders Centers of the Mid-Atlantic (SDCMA), Glen Burnie

28562

Coastal Carolina Health Care, P.A., New Bern

29201

Bogan Sleep Consultants LLC, Columbia

29615

Velocity Clinical Research, Greenville

30328

NeuroTrials Research, Inc., Atlanta

33024

Research Centers of America -- Hollywood, Hollywood

33176

Sleep Medicine Specialists of South Florida, Miami

33511

Teradan Clinical Trials, Brandon

45212

CTI Clinical Research Center, Cincinnati

45245

Intrepid Research, Cincinnati

48314

Sleep and Attention Disorders Institute, Sterling Heights

48377

Henry Ford Hospital, Detroit

55125

Minnesota Lung Center / Minnesota Sleep Institute, Woodbury

60634

Chicago Research Center, Chicago

63017

St. Luke's Hospital Sleep Medicine, Chesterfield

63143

Clayton Sleep Institute, Maplewood

78731

FutureSearch Trials of Neurology, Austin

80918

Delta Waves, Colorado Springs

90025

Santa Monica Clinical Trials, Los Angeles

92103

Pacific Research Network, San Diego

92705

SDS Clinical Trials, Inc., Santa Ana

02459

Neurocare, Newton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Apnimed

INDUSTRY